2seventy bio Newsroom

Buy Rating Affirmed for 2seventy Bio on Strong Growth Prospects and Financial Stability

TipRanksMay 10 01:33 ET

2seventy bio | 10-Q: Quarterly report

Futu NewsMay 9 16:10 ET · Announcements

2seventy Bio Is Maintained at Buy by Canaccord Genuity

2seventy Bio Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 9 15:18 ET

Express News | Canaccord Genuity Maintains Buy on 2seventy Bio, Lowers Price Target to $11

BenzingaMay 9 15:08 ET

2seventy Bio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 147.19% Canaccord Genuity $12 → $11 Maintains Buy 04/08/2024 169.66% Citigroup $9 → $12 Maintai

BenzingaMay 9 15:06 ET

2seventy Bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 9 13:21 ET

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), 2seventy Bio (TSVT) and Marinus (MRNS)

TipRanksMay 9 07:01 ET

2seventy Bio Inc (TSVT) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and ...

Yahoo FinanceMay 9 03:06 ET

Q1 2024 2Seventy Bio Inc Earnings Call

Yahoo FinanceMay 8 22:23 ET

2seventy Bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 8 15:15 ET

2seventy Bio Inc (TSVT) Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Realignments

Yahoo FinanceMay 8 08:39 ET

2seventy Bio Q1 Adj $(0.81), Inline, Sales $12.44M Miss $14.08M Estimate

2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(1.08) per share from the same period

BenzingaMay 8 07:08 ET

Express News | 2Seventy Bio Inc Q1 Shr View $-0.81 -- Lseg Ibes Data

ReutersMay 8 07:05 ET

Express News | 2Seventy Bio Inc - Qtrly Net Loss per Share - Basic and Diluted $1.01

ReutersMay 8 07:05 ET

2seventy Bio 1Q Loss $52.7M >TSVT

2seventy Bio 1Q Loss $52.7M >TSVT

Dow JonesMay 8 07:05 ET

2seventy Bio 1Q Loss/Shr $1.01 >TSVT

2seventy Bio 1Q Loss/Shr $1.01 >TSVT

Dow JonesMay 8 07:05 ET

2seventy Bio 1Q Rev $12.4M >TSVT

2seventy Bio 1Q Rev $12.4M >TSVT

Dow JonesMay 8 07:05 ET

Express News | 2Seventy Bio Inc - Ended Quarter With $181.4 Mln Cash, Cash Equivalents, and Marketable Securities; Cash Runway Beyond 2027

ReutersMay 8 07:04 ET

Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, Vs. Street Est of $14.1M

07:02 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M

MT NewswiresMay 8 07:02 ET

Press Release: 2seventy Bio Reports First Quarter Financial Results and Recent Operational Progress

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines

Dow JonesMay 8 07:02 ET